Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Sell
41
IGMS Quote, Financials, Valuation and Earnings
Last price:
$1.27
Seasonality move
:
-10.54%
Day range:
$1.29 - $1.40
52-week range:
$0.92 - $22.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
30.60x
P/B ratio:
116.27x
Volume:
367.9K
Avg. volume:
180.3K
1-year change:
-82.51%
Market cap:
$81.2M
Revenue:
$2.7M
EPS (TTM):
-$3.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IGMS
IGM Biosciences
|
$4.3M | -$0.45 | -100% | -45.57% | $1.94 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.28 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IGMS
IGM Biosciences
|
$1.35 | $1.94 | $81.2M | -- | $0.00 | 0% | 30.60x |
|
ATNM
Actinium Pharmaceuticals
|
$1.77 | $5.00 | $55.2M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.60 | $0.85 | $3.5M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.53 | -- | $24.6M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$4.51 | $1.00 | $3.2M | -- | $0.00 | 0% | 1.44x |
|
TOVX
Theriva Biologics
|
$0.50 | $7.00 | $4.1M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IGMS
IGM Biosciences
|
-- | -0.977 | -- | 5.39x |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.250 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.941 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.642 | -- | -- |
|
OGEN
Oragenics
|
-- | -1.150 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.651 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IGMS
IGM Biosciences
|
-- | -$32.9M | -241.68% | -241.68% | -6590.58% | -$32.6M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
IGM Biosciences vs. Competitors
-
Which has Higher Returns IGMS or ATNM?
Actinium Pharmaceuticals has a net margin of -10599.6% compared to IGM Biosciences's net margin of -11511.11%. IGM Biosciences's return on equity of -241.68% beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital IGMSIGM Biosciences-- -$0.86 $698K ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About IGMS or ATNM?
IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 182.49%. Given that Actinium Pharmaceuticals has higher upside potential than IGM Biosciences, analysts believe Actinium Pharmaceuticals is more attractive than IGM Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings IGMSIGM Biosciences0 4 0 ATNMActinium Pharmaceuticals2 1 0 -
Is IGMS or ATNM More Risky?
IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.271, suggesting its less volatile than the S&P 500 by 127.061%.
-
Which is a Better Dividend Stock IGMS or ATNM?
IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGMS or ATNM?
IGM Biosciences quarterly revenues are $499K, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. IGM Biosciences's net income of -$52.9M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGMSIGM Biosciences30.60x -- $499K -$52.9M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns IGMS or NBY?
NovaBay Pharmaceuticals has a net margin of -10599.6% compared to IGM Biosciences's net margin of -49.65%. IGM Biosciences's return on equity of -241.68% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital IGMSIGM Biosciences-- -$0.86 $698K NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About IGMS or NBY?
IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 42.59%. Given that IGM Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe IGM Biosciences is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IGMSIGM Biosciences0 4 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is IGMS or NBY More Risky?
IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.
-
Which is a Better Dividend Stock IGMS or NBY?
IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGMS or NBY?
IGM Biosciences quarterly revenues are $499K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGM Biosciences's net income of -$52.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, IGM Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGMSIGM Biosciences30.60x -- $499K -$52.9M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns IGMS or NNVC?
Nanoviricides has a net margin of -10599.6% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -241.68% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IGMSIGM Biosciences-- -$0.86 $698K NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About IGMS or NNVC?
IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 324.84%. Given that Nanoviricides has higher upside potential than IGM Biosciences, analysts believe Nanoviricides is more attractive than IGM Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings IGMSIGM Biosciences0 4 0 NNVCNanoviricides0 0 0 -
Is IGMS or NNVC More Risky?
IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.
-
Which is a Better Dividend Stock IGMS or NNVC?
IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGMS or NNVC?
IGM Biosciences quarterly revenues are $499K, which are larger than Nanoviricides quarterly revenues of --. IGM Biosciences's net income of -$52.9M is lower than Nanoviricides's net income of -$2.2M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGMSIGM Biosciences30.60x -- $499K -$52.9M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns IGMS or OGEN?
Oragenics has a net margin of -10599.6% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -241.68% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IGMSIGM Biosciences-- -$0.86 $698K OGENOragenics-- -$3.60 -- -
What do Analysts Say About IGMS or OGEN?
IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 565.26%. Given that Oragenics has higher upside potential than IGM Biosciences, analysts believe Oragenics is more attractive than IGM Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings IGMSIGM Biosciences0 4 0 OGENOragenics0 1 0 -
Is IGMS or OGEN More Risky?
IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.
-
Which is a Better Dividend Stock IGMS or OGEN?
IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGMS or OGEN?
IGM Biosciences quarterly revenues are $499K, which are larger than Oragenics quarterly revenues of --. IGM Biosciences's net income of -$52.9M is lower than Oragenics's net income of -$2.2M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus 1.44x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGMSIGM Biosciences30.60x -- $499K -$52.9M OGENOragenics1.44x -- -- -$2.2M
-
Which has Higher Returns IGMS or TOVX?
Theriva Biologics has a net margin of -10599.6% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -241.68% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IGMSIGM Biosciences-- -$0.86 $698K TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About IGMS or TOVX?
IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1314.14%. Given that Theriva Biologics has higher upside potential than IGM Biosciences, analysts believe Theriva Biologics is more attractive than IGM Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings IGMSIGM Biosciences0 4 0 TOVXTheriva Biologics1 1 0 -
Is IGMS or TOVX More Risky?
IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.
-
Which is a Better Dividend Stock IGMS or TOVX?
IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGMS or TOVX?
IGM Biosciences quarterly revenues are $499K, which are larger than Theriva Biologics quarterly revenues of --. IGM Biosciences's net income of -$52.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGMSIGM Biosciences30.60x -- $499K -$52.9M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Where Will Exxon Stock Be in 5 Years?
For sure Exxon Mobil (NYSE: XOM) is no hyped-up AI…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
75
INSM alert for Jun 11
Insmed [INSM] is up 7.75% over the past day.
Sell
25
AAON alert for Jun 11
AAON [AAON] is down 3.49% over the past day.
Buy
58
EXOD alert for Jun 11
Exodus Movement [EXOD] is down 8.21% over the past day.
